Health

Add as a preferred source on Google

Eisai and Biogen Report Five-Year Leqembi Results Against External Cohorts

The companies reported a 2.05-point CDR-SB gap versus ADNI at year five. The long-term comparison used external datasets after Clarity AD’s randomized placebo phase ended at 18 months.

Updated 2 min read
Attendees examine Alzheimer’s research posters during a conference at Boston Marriott Copley Place. / EconoTimes.ai
Attendees examine Alzheimer’s research posters during a conference at Boston Marriott Copley Place. / EconoTimes.ai

Eisai and Biogen said five-year follow-up from Clarity AD showed a wider difference in cognitive scores versus external Alzheimer’s cohorts, extending the reported comparison beyond the trial’s randomized phase.

The companies presented the results Nov. 16 at the 19th Clinical Trials on Alzheimer’s Disease conference in Boston. At five years, the mean change from baseline on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) was 2.05 points below the estimate based on Alzheimer’s Disease Neuroimaging Initiative (ADNI) data. The gap was 1.00 point at year three. Against BioFINDER estimates, the differences were 2.54 points at five years and 1.42 points at three years. Higher CDR-SB totals correspond to greater impairment.

Clarity AD enrolled 1,795 people with early Alzheimer’s disease. The study initially assigned 898 participants to lecanemab and 897 to placebo, with the randomized core phase lasting 18 months. Long-term extension enrollment included 95% of core-study completers. The companies reported that 351 patients stayed on lecanemab throughout the five-year period.

For the extended analysis, the companies set patient outcomes alongside estimates from ADNI and BioFINDER. There was no randomized placebo group followed for the full five years. EconoTimes previously covered the companies’ plan to present five-year findings at CTAD.

In a CDR-SB stage analysis using ADNI data, Eisai and Biogen reported a 36% lower relative risk of progressing to the next disease stage. By year five, 61.9% of the lecanemab group had advanced, compared with 77.5% in ADNI. For progression from early disease to moderate or severe dementia, the reported five-year proportions were 31.0% among lecanemab recipients and 48.7% in ADNI; the companies calculated a 49% lower relative risk for the treated group.

Among patients in the low-tau subgroup, 62% improved on the CDR-SB after five years, while 66% were stable or improved. The companies said their five-year safety update identified no additional findings. ARIA-E incidence was 13.5% in the first 12-month treatment interval, then 3.6%, 1.1%, 1.3% and 0.6% in the next four intervals. The placebo rate was 1.7% over 18 months.

Related articles

View all